hero image
Webinar

Immunosuppressive and biologic therapy

The utility of interferon-gamma release assays (IGRAs) for patients

On-demand
icon_0085_cc_gen_calendar-s
Aug 20, 2025
icon_0310_cc_gen_timeinterval-s
38 minutes

In this on-demand webinar, you’ll learn:

icon_0153_cc_gen_source_okay-s

How TB risks are elevated by immunosuppressive therapies, including TNF-alpha inhibitors

icon_0153_cc_gen_source_okay-s

Why IGRAs are preferred over skin tests in rheumatology patients

icon_0153_cc_gen_source_okay-s

How to navigate indeterminate results and retesting protocols

icon_0153_cc_gen_source_okay-s

What the American College of Rheumatology recommends for TB screening

icon_0153_cc_gen_source_okay-s

Steps to take before initiating biologic therapy

About this webinar

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases. For patients on immunosuppressive therapies, screening is critical — but also complex. Fortunately, innovations in testing offer a faster, more accurate path forward.

Join rheumatologist Dr. Shereen Mahmood as she explores TB testing strategies for immunocompromised patients and explains why interferon gamma release assays (IGRAs) like QuantiFERON-TB Gold Plus are recommended for use in patients on biologics.

Speakers